The oral drug Roxadustat (code FG-4592) capsule is the first small molecule hypoxic-inducing factor prolyl hydroxylase inhibitor (HIF-PHI) developed in the world for the treatment of renal anemia. The physiological effects of hypoxic inducible factor (HIF) not only increase the expression of erythropoietin, but also increase the expression of erythropoietin receptors and proteins that promote iron absorption and circulation. Roxallistat inhibits PH enzymes by simulating ketoglutaric acid, one of the substrates of prolyl hydroxylase (PH), and affects the role of PH enzymes in maintaining the balance between the rate of HIF production and degradation, thus achieving the purpose of correcting anemia. The marketing of Roxastat capsule will provide a new treatment for anemia patients caused by chronic kidney disease.